Checkpoint Inhibitor Monotherapy in Potentially Trial-Eligible or Trial-Ineligible Patients With Metastatic NSCLC in the German Prospective CRISP Registry Real-World Cohort (AIO-TRK-0315)

Frank Griesinger; Dimitri Flieger; Dirk Behringer; Juliana Ababei; Harald-Robert Bruch; Maike de Wit; Petros Christopoulos; W. Berger; Stefan Bauer; Wilko Weichert; Lutz Dietze; Martin Faehling; Martina Jänicke; M Boesche; Steffen Dörfel; Stefan Zacharias; Thomas Fietz; A. Ammon; Ivo Azeh; Wolfgang M. Brueckl; Reinhard Depenbusch; A. Fleitz; Markus Dommach; Till‐Oliver Emde; Bastian Jaeschke; Annika Groth; Jürgen Anhuf; Jens Kern; Tobias Dechow; Wilfried Eberhardt; W. Elsel; Jürgen R. Fischer; Corinna Elender; Sabine Bohnet; Claas Wesseler; A. Hipper; Horst-Dieter Hummel; Michael Thomas; Jürgen Alt; Klaus‐Ulrich Däßler; W. Brückl; Mathias Bertram; Jan Schröder; Jochen Wilke; Christiane Bernhardt; Ulrike Burkhard‐Meier; Volker Petersen; Martin Sebastian

doi:10.1016/j.jtocrr.2023.100626

Checkpoint Inhibitor Monotherapy in Potentially Trial-Eligible or Trial-Ineligible Patients With Metastatic NSCLC in the German Prospective CRISP Registry Real-World Cohort (AIO-TRK-0315)

Frank Griesinger(Carl von Ossietzky Universität Oldenburg), Dimitri Flieger(Klinikum Aschaffenburg), Dirk Behringer(Augusta-Kranken-Anstalt), Juliana Ababei, Harald-Robert Bruch, Maike de Wit(Florida Hospital Cancer Institute), Petros Christopoulos(Thorax Foundation), W. Berger, Stefan Bauer(Iomedico (Germany)), Wilko Weichert(Deutsches Konsortium für Translationale Krebsforschung), Lutz Dietze, Martin Faehling(Klinikum Esslingen), Martina Jänicke(Iomedico (Germany)), M Boesche(Heidelberg University), Steffen Dörfel(Onkozentrum Dresden), Stefan Zacharias(Iomedico (Germany)), Thomas Fietz(Praxis für Hämatologie und Onkologie), A. Ammon, Ivo Azeh, Wolfgang M. Brueckl(Paracelsus Medizinische Privatuniversität), Reinhard Depenbusch(Rambam Health Care Campus), A. Fleitz(Iomedico (Germany)), Markus Dommach, Till‐Oliver Emde, Bastian Jaeschke(Helios Dr. Horst Schmidt Kliniken Wiesbaden), Annika Groth(AIO Studien gGmbH), Jürgen Anhuf, Jens Kern(Klinikum Würzburg Mitte), Tobias Dechow, Wilfried Eberhardt(National Center for Tumor Diseases), W. Elsel(Paracelsus Medizinische Privatuniversität), Jürgen R. Fischer, Corinna Elender(Klinikum Dortmund), Sabine Bohnet(University Hospital Schleswig-Holstein), Claas Wesseler(Asklepios Klinikum Harburg), A. Hipper(AIO Studien gGmbH), Horst-Dieter Hummel(Comprehensive Cancer Center Mainfranken), Michael Thomas, Jürgen Alt(University of Applied Sciences Mainz), Klaus‐Ulrich Däßler, W. Brückl(Nuremberg Hospital), Mathias Bertram, Jan Schröder(Praxis für Hämatologie und Onkologie), Jochen Wilke(Praxis für Hämatologie und Onkologie), Christiane Bernhardt, Ulrike Burkhard‐Meier, Volker Petersen(Praxis für Hämatologie und Onkologie), Martin Sebastian(Goethe University Frankfurt)

JTO Clinical and Research Reports

December 25, 2023

10.1016/j.jtocrr.2023.100626

Cited by 4

|IEEE Transactions on Medical Imaging|2014|6.7k

Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer

|New England Journal of Medicine|2013|3.4k

Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer

|New England Journal of Medicine|2016|3.3k

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

|The Lancet|2019|2.6k

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

|The Lancet Oncology|2015|1.6k

Checkpoint Inhibitor Monotherapy in Potentially Trial-Eligible or Trial-Ineligible Patients With Metastatic NSCLC in the German Prospective CRISP Registry Real-World Cohort (AIO-TRK-0315)

Related Papers